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Abstract
Background and Motivation: The Prokineticin receptor (PKR) 1 and 2 subtypes are novel members of family A GPCRs, which
exhibit an unusually high degree of sequence similarity. Prokineticins (PKs), their cognate ligands, are small secreted
proteins of ,80 amino acids; however, non-peptidic low-molecular weight antagonists have also been identified. PKs and
their receptors play important roles under various physiological conditions such as maintaining circadian rhythm and pain
perception, as well as regulating angiogenesis and modulating immunity. Identifying binding sites for known antagonists
and for additional potential binders will facilitate studying and regulating these novel receptors. Blocking PKRs may serve as
a therapeutic tool for various diseases, including acute pain, inflammation and cancer.
Methods and Results: Ligand-based pharmacophore models were derived from known antagonists, and virtual screening
performed on the DrugBank dataset identified potential human PKR (hPKR) ligands with novel scaffolds. Interestingly, these
included several HIV protease inhibitors for which endothelial cell dysfunction is a documented side effect. Our results
suggest that the side effects might be due to inhibition of the PKR signaling pathway. Docking of known binders to a 3D
homology model of hPKR1 is in agreement with the well-established canonical TM-bundle binding site of family A GPCRs.
Furthermore, the docking results highlight residues that may form specific contacts with the ligands. These contacts provide
structural explanation for the importance of several chemical features that were obtained from the structure-activity
analysis of known binders. With the exception of a single loop residue that might be perused in the future for obtaining
subtype-specific regulation, the results suggest an identical TM-bundle binding site for hPKR1 and hPKR2. In addition,
analysis of the intracellular regions highlights variable regions that may provide subtype specificity.
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Introduction
Prokineticins and their receptors
Mammalian prokineticins 1 and 2 (PK1 and PK2) are two
secreted proteins of about 80–90 residues in length, which belong
to the AVIT protein family [1,2,3]. Their structure includes 10
conserved cysteine residues that create five disulphide-bridged
motifs (colipase fold) and an identical (AVIT) motif in the N-
terminus.
PKs are expressed in a wide range of peripheral tissues,
including the nervous, immune, and cardiovascular systems, as
well as in the steroidogenic glands, gastrointestinal tract, and bone
marrow [3,4,5,6].
PKs serve as the cognate ligands for two highly similar G-
protein-coupled receptors (GPCRs) termed PKs receptor subtypes
1 and 2 (hPKR1 and hPKR2 in humans) [5,7,8]. These receptors
are characterized by seven membrane-spanning a-helical segments
separated by alternating intracellular and extracellular loop
regions. The two subtypes are unique members of family A
GPCRs in terms of subtype similarity, sharing 85% sequence
identity – a particularly high value among known GPCRs. For
example, the sequence identity between the b1 and b2-adrenergic
receptor subtypes, which are well established drug targets, is 57%.
Most sequence variation between the hPKR subtypes is concen-
trated in the extracellular N terminal region, which contains a
nine-residue insert in hPKR1 compared with hPKR2, as well as in
the second intracellular loop (ICL2) and in the C terminal tail
(Figure 1).
PKR1 is mainly expressed in peripheral tissues, such as the
endocrine organs and reproductive system, the gastrointestinal
tract, lungs, and the circulatory system [8,9], whereas PKR2,
which is also expressed in peripheral endocrine organs [8], is the
main subtype in the central nervous system. Interestingly, PKR1 is
expressed in endothelial cells of large vessels while PKR2 is
strongly expressed in fenestrated endothelial cells of the heart and
corpus luteum [10,11]. Expression analysis of PKRs in heteroge-
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nanomolar concentrations of both recombinant PKs, though PK2
was shown to have a slightly higher affinity for both receptors than
was PK1 [12]. Hence, in different tissues, specific signaling
outcomes following receptor activation may be mediated by
different ligand-receptor combinations, in accordance with the
expression profile of both ligands and receptors in that tissue [13].
Activation of PKRs leads to diverse signaling outcomes, including
mobilization of calcium, stimulation of phosphoinositide turnover,
and activation of the p44/p42 MAPK cascade in overexpressed
cells, as well as in endothelial cells naturally expressing PKRs
[5,7,8,14,15] leading to the divergent functions of PKs. Differen-
tial signaling capabilities of the PKRs is achieved by coupling to
several different G proteins, as previously demonstrated [11].
The PKR system is involved in different pathological conditions
such as heart failure, abdominal aortic aneurysm, colorectal
cancer, neuroblastoma, polycystic ovary syndrome, and Kallman
syndrome [16]. While Kallman syndrome is clearly linked to
mutations in the PKR2 gene, it is not currently established
whether the other diverse biological functions and pathological
conditions are the result of a delicate balance of both PKR
subtypes or depend solely on one of them.
Recently, small-molecule, non-peptidic PKR antagonists have
been identified through a high-throughput screening procedure
[17,18,19,20]. These guanidine triazinedione-based compounds
competitively inhibit calcium mobilization following PKR activa-
tion by PKs in transfected cells, in the nanomolar range [17].
However, no selectivity for one of the subtypes has been observed
[17].
A better understanding of the PK system can generate
pharmacological tools that will affect diverse areas such as
development, immune response, and endocrine function. There-
fore, the molecular details underlying PK receptor interactions,
both with their cognate ligands and small-molecule modulators,
and with downstream signaling partners, as well as the molecular
basis of differential signaling, are of great fundamental and applied
interest.
Structural information has been instrumental in delineating
interactions and the rational development of specific inhibitors
[21]. However, for many years only the X-ray structure of bovine
Rhodopsin has been available [22] as the sole representative
structure of the large superfamily of seven-transmembrane (7TM)
domain GPCRs.
In recent years crystallographic data on GPCRs has significantly
grown and now includes, for example, structures of the b1 and b2-
adrenergic receptors, in both active and inactive states, the
agonist- and antagonist-bound A2A adenosine receptor, and the
CXCR4 chemokine receptor bound to small-molecule and
peptide antagonists. The new structures were reviewed in
[23,24] and ligand-receptor interactions were summarized in
[25]. Nevertheless, the vast number of GPCR family members still
requires using computational 3D models of GPCRs for studying
these receptors and for drug discovery. Different strategies for
GPCR homology modeling have been developed in recent years
(reviewed in [26]), and these models have been successfully used
for virtual ligand screening (VLS) procedures, to identify novel
GPCR binders [21].
Successful in-silico screening approaches, applied to GPCR drug
discovery, include both structure-based and ligand-based tech-
niques and their combinations. Molecular ligand docking is the
most widely used computational structure-based approach,
employed to predict whether small-molecule ligands from a
Figure 1. Snake plot of hPKR1. The secondary structure is according to hPKR1 protein annotation in the UniProtKB database (entry Q8TCW9).
Positions in the hPKR1 sequence differing from hPKR2 (entry Q8NFJ6) are shaded black. Conserved positions between the two subtypes are shaded
white. A nine-residue hPKR1-unique insert in the N terminus is shaded gray with dashed lines. The seven transmembrane domains are denoted by
roman numerals. Extracellular and intracellular sides of the membrane are labeled, as well as the N terminus (NH2) and C terminus (COOH) ends of the
protein.
doi:10.1371/journal.pone.0027990.g001
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ligand-receptor complex is available, either from an X-ray
structure or an experimentally verified model, a structure-based
pharmacophore model describing the possible interaction points
between the ligand and the receptor can be generated using
different algorithms and later used for screening compound
libraries [27]. In ligand-based VLS procedures, the pharmaco-
phore is generated via superposition of 3D structures of several
known active ligands, followed by extracting the common
chemical features responsible for their biological activity. This
approach is often used when no reliable structure of the target is
available [28].
In this study, we analyzed known active small-molecule
antagonists of hPKRs vs. inactive compounds to derive ligand-
based pharmacophore models. The resulting highly selective
pharmacophore model was used in a VLS procedure to identify
potential hPKR binders from the DrugBank database. The
interactions of both known and predicted binders with the
modeled 3D structure of the receptor were analyzed and
compared with available data on other GPCR-ligand complexes.
This supports the feasibility of binding in the TM-bundle and
provides testable hypotheses regarding interacting residues. The
potential cross-reactivity of the predicted binders with the hPKRs
was discussed in light of prospective ’off-target’ effects. The
challenges and possible venues for identifying subtype-specific
binders are addressed in the discussion section.
Materials and Methods
Homology Modeling and Refinement
All-atom homology models of human PKR1 and PKR2 were
generated using the I-TASSER server [29], which employs a
fragment-based method. Here a hierarchical approach to protein
structure modeling is used in which fragments are excised from
multiple template structures and reassembled, based on threading
alignments. Sequence alignment of modeled receptor subtypes and
the structural templates were generated by the TCoffee server
[30]; this information is available in the Supporting Information as
figure S1. A total of 5 models per receptor subtype were obtained.
The model with the highest C-score (a confidence score calculated
by I-Tasser) for each receptor subtype, was exported to Discovery
Studio 2.5 (DS2.5; Accelrys, Inc.) for further refinement. In DS2.5,
the model quality was assessed using the protein report tool, and
the models were further refined by energy minimization using the
CHARMM force field [31]. The models were then subjected to
side-chain refinement using the SCWRL4 program [32], and to an
additional round of energy minimization using the Smart
Minimizer algorithm, as implemented in DS2.5. The resulting
models were visually inspected to ensure that the side chains of the
most conserved residues in each helix are aligned to the templates.
An example of these structural alignments appears in figure S2.
For validation purposes, we also generated homology models of
the turkey b1 adrenergic receptor (b1adr) and the human b2
adrenergic receptor (b2adr). The b1adr homology model is based
on 4 different b2adr crystal structures (PDB codes – 3SN6, 2RH1,
3NY8, and 3d4S); the b2adr model is based on the crystal
structures of b1adr (2VT4, 2YCW), the Dopamine D3 receptor
(3PBL), and the histamine H1 receptor (3RZE). The models were
subjected to the same refinement procedure as previously
described, namely, deletion of loops, energy minimization, and
side chain refinement, followed by an additional step of energy
minimization. Sometimes the side chain rotamers were manually
adjusted, following the aforementioned refinement procedure.
Throughout this article, receptor residues are referred to by
their one-letter code, followed by their full sequence number in
hPKR1. TM residues also have a superscript numbering system
according to Ballesteros-Weinstein numbering [33]; the most
conserved residue in a given TM is assigned the index X.50, where
X is the TM number, and the remaining residues are numbered
relative to this position.
Identification of a 7TM-bundle binding site
The location of a potential small-molecule-TM binding cavity
was identified based on (1) identification of receptor cavities using
the "eraser" and "flood-filling" algorithms [34], as implemented in
DS2.5 and (2) use of two energy-based methods that locate
energetically favorable binding sites – Q-SiteFinder [35], an
algorithm that uses the interaction energy between the protein and
a simple Van der Waals probe to locate energetically favorable
binding sites, and SiteHound [36], which uses a carbon probe to
similarly identify regions of the protein characterized by favorable
interactions. A common site that encompasses the results from the
latter two methods was determined as the TM-bundle binding site
for small molecules.
SAR Analysis
A dataset of 107 small-molecule hPKR antagonists was
assembled from the literature [18,19]. All ligands were built using
DS2.5. pKa values were calculated for each ionazable moiety on
each ligand, to determine whether the ligand would be charged
and which atom would be protonated at a biological pH of 7.5. All
ligands were then subjected to the "Prepare Ligands" protocol, to
generate tautomers and enantiomers, and to set standard formal
charges.
For the SAR study, the dataset was divided into two parts: (1)
active molecules, with IC50 values below 0.05 mM, and (2) inactive
molecules, with IC50 values above 1 mM. IC50 values were
measured in the calcium mobilization assay [18,19]. When
possible, the molecules were divided into pairs of active and
inactive molecules that differ in only one chemical group, and all
possible pharmacophore features were computed using the
"Feature mapping" protocol (DS 2.5). These pairs were then
compared to determine those pharmacophore features’ impor-
tance for biological activity.
Ligand-Based Pharmacophore Models
The HipHop algorithm [37], implemented in DS2.5, was used
for constructing ligand-based pharmacophore models. This
algorithm derives common features of pharmacophore models
using information from a set of active compounds. The two most
active hPKR antagonists (the lowest IC50 values in the Janssen
patent [19,20]) were selected as ‘reference compounds’ from the
data set described above, and an additional antagonist molecule
with a different scaffold was added from a dataset recently
published [38], and were used to generate the models (figure S3).
Ten models in total were generated, presenting different
combinations of chemical features. These models were first
evaluated by their ability to successfully recapture all known
active hPKR antagonists. An enrichment study was performed to
evaluate the pharmacophore models. The dataset contains 56
active PKR antagonists seeded in a random library of 5909 decoys
retrieved from the ZINC database [39]. The decoys were selected
so that they will have general and chemical properties similar to
the known hPKR antagonists (by filtering the ZINC database
according to the average molecular properties of known hPKR
antagonists 6 4 Standard Deviation range). In this way,
enrichment is not simply achieved by separating trivial features
Small-Molecule Binders of Prokineticin Receptors
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(a log of the calculated octanol-water partition coefficient, which
measures the extent of a substance hydrophilicity or hydrophobic-
ity), molecular weight, formalcharge,the numberofhydrogen bond
donors and acceptors, and the number of rotatable bonds. All
molecules were prepared as previously described, and a conforma-
tional set of 50 "best-quality" low-energy conformations was
generated for each molecule. All conformers within 20 kcal/mol
from the global energy minimum were included in the set. The
dataset was screened using the "ligand pharmacophore mapping"
protocol (DS2.5), with the minimum interference distance set to 1A ˚
and the maximum omitted features set to 0. All other protocol
parameters were maintained at the default settings.
To analyze enrichment results and select the best pharmaco-
phore model for subsequent virtual screening, ROC curves were
constructed for each model, where the fraction of identified known
binders (true positives, representing sensitivity) was plotted against
the fraction of identified library molecules (false positives; 1-
specificity). Based on this analysis, the best pharmacophore model
was selected for virtual screening purposes.
Generation of the DrugBank data set and virtual
screening
The DrugBank database [40] (release 2.0), which contains
,4900 drug entries, including 1382 FDA-approved small-
molecule drugs, 123 FDA-approved biotech (protein/peptide)
drugs, 71 nutraceuticals, and over 3240 experimental drugs, was
used for Virtual Screening. The database was filtered, based on
the average molecular properties of known hPKR antagonists 6
4SD (standard deviation). These properties included AlogP,
molecular weight, the number of hydrogen bond donors and
acceptors, the formal charge, and the number of rotatable bonds.
The liberal 64SD interval was chosen because the calculated
range of molecular properties of the known antagonists was very
narrow. Molecules were retained only if their formal charge was
neutral or positive, since the known compounds were positively
charged. This resulted in a test set containing 432 molecules. All
molecules were prepared as previously described, and a set of 50
"best-quality" low-energy conformations was generated for each
molecule; all conformations were within 20 kcal/mol from the
global energy minimum.
The data set was screened against the pharmacophore model
(chosen from the ROC analysis) using the "ligand pharmacophore
mapping" protocol in DS2.5. All protocol settings were maintained
at default settings except for minimum interference distance,
which was set to 1A ˚ and the maximum omitted features was set to
0. To prioritize the virtual hits, fit values were extracted, to reflect
the quality of molecule mapping onto the pharmacophore. Only
molecules with fit values above the enrichment ROC curve cutoff
that identifies 100% of the known PKR antagonists (FitVa-
lue>2.85746) were retained as virtual hits for further analysis.
The similarity between the virtual hits and known small-
molecule PKR antagonists was evaluated by calculating the
Tanimoto coefficient distance measure using the ’Find similar
molecules by fingerprints’ module in DS2.5, which calculates the
number of AND bits normalized by the number of OR bits,
according to SA/(SA+SB+SC), where SA is the number of AND bits
(bits present in both the target and the reference), SB is the number
of bits in the target but not the reference, and SC is the number of
bits in the reference but not the target.
Small-Molecule Docking
Molecular docking of the small-molecule hPKR antagonists
dataset (active and inactive molecules), as well as of virtual hits, to
the hPKR1 homology model, was performed using LigandFit [34]
as implemented in DS2.5. LigandFit is a shape complementary-
based algorithm that performs flexible ligand-rigid protein
docking. In our experiments, the binding site was defined as a
284.8 A ˚ 3 TM cavity area, surrounded by binding site residues
identified using the energy-based methods described above.
Default algorithm settings were used for docking. The final ligand
poses were selected based on their empirical LigScore docking
score [41]. Here we used the (default) Dreiding force field to
calculate the VdW interactions.
All docking experiments were conducted on a model without
extracellular and intracellular loops. Loop configurations are
highly variable among the GPCR crystal structures [42].
Therefore, deleting the loops in order to reduce the uncertainty
stemming from inaccurately predicted loops is a common practice
in the field [43,44,45].
To further validate our protocol, we also performed molecular
redocking of the small-molecule partial inverse agonist carazolol
and the antagonist cyanopindolol to their original X-ray structures
from which loops were deleted, and to loopless homology models
of b1adr and b2adr using LigandFit, as previously described. As in
the case of docking to the hPKR1 model, this procedure was
performed on loopless X-ray structures and models. The binding
site was identified from receptor cavities using the "eraser" and
"flood-filling" algorithms, as implemented in DS2.5. The highest
scoring LigScore poses were selected as the representative
solutions. The ligand-receptor poses were compared to the
corresponding X-ray complexes by (1) calculating the root mean
square deviation (RMSD) of heavy ligand atoms from their
respective counterparts in the crystallized ligand after superposi-
tion of the docked ligand-receptor complex onto the X-ray
structure; (2) calculating the number of correct atomic contacts in
the docked ligand-receptor complex compared with the X-ray
complex, where an atomic contact is defined as a pair of heavy
ligand and protein atoms located at a distance of less than 4A ˚; and
by (3) comparing the overall number of correctly predicted
interacting residues in the docked complex to the X-ray complex
(where interacting residues are also defined as residues located less
than 4A ˚ from the ligand).
Small-molecule docking analysis
The resulting ligand poses of the known hPKR antagonists were
analyzed to identify all ligand-receptor hydrogen bonds, charged
interactions, and hydrophobic interactions.
The specific interactions formed between the ligand and
binding site residues were quantified to determine the best scoring
pose of each ligand (active and inactive). For each ligand pose, a
vector indicating whether this pose forms a specific hydrogen bond
and/or hydrophobic p interaction with each of the binding site
residues was generated. The data were hierarchically clustered
using the clustergram function of the bioinformatics toolbox in
Matlab version 7.10.0.499 (R2010a). The pairwise distance
between these vectors was computed using the Hamming distance
method, which calculates the percentage of coordinates that differ.
For a m-by-n data matrix X, which is treated as m (1-by-n) row
vectors x1, x2, …, xm, the distance between the vector xs and xt is
defined as follows:
dst~ # xsj=xtj

=n

where # is the number of vectors that differ.
The poses of the virtual hits ligands were further filtered using
structure-based constraints derived from analyzing the interactions
between known PKR antagonists and the receptor, obtained in the
Small-Molecule Binders of Prokineticin Receptors
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included (1) an electrostatic interaction between the ligand and
Glu119
2.61, (2) at least one hydrogen bond between the ligand and
Arg144
3.32, and/or Arg307
6.58, and (3) at least two hydrophobic
interactions (p-p or p-cation) between the ligand and Arg144
3.32
and/or Arg307
6.58.
Evolutionary selection analysis
Evolutionary selection analysis of the PKR subtypes’ coding
DNA sequences was carried out using the Selecton server (version
2.4) [46,47]. The Selecton server is an on-line resource which
automatically calculates the ratio (v) between non-synonymous
(Ka) and synonymous (Ks) substitutions, to identify the selection
forces acting at each site of the protein. Sites with v.1 are
indicative of positive Darwinian selection, and sites with v,1
suggest purifying selection. As input, we used the homologous
coding DNA sequences of 13 mammalian species for each subtype,
namely, human, rat, mouse, bovine, rabbit, panda, chimpanzee,
orangutan, dog, gorilla, guinea pig, macaque and marmoset. We
used the default algorithm options and the obtained results were
tested for statistical significance using the likelihood ratio test, as
implemented in the server.
Results
SAR analysis highlights molecular features essential for
small-molecule antagonistic activity
A review of the literature revealed a group of non-peptidic
compounds that act as small-molecule hPKR antagonists, with no
apparent selectivity toward one of the subtypes [17,18,19,20,38].
The reported compounds have either a guanidine triazinedione or
a morpholine carboxamide scaffold. We decided to perform
structure-activity relationship (SAR) analysis of the triazine-based
compounds, owing to the more detailed pharmacological data
available for these compounds [17,18,19,20].
SAR analysis of the reported molecules with and without
antagonistic activity toward hPKR provides hints about the
geometrical arrangement of chemical features essential for the
biological activity. By comparing pairs of active and inactive
compounds that differ in only one functional group, one can
determine the activity-inducing chemical groups at each position.
To this end, we constructed a dataset of 107 molecules
identified by high-throughput screening. This included 51
molecules that we defined as inactive (Ca
2+ mobilization IC50
higher than 1 mM), and 56 molecules defined as active (IC50 below
0.05 mM). All compounds share the guanidine triazinedione
scaffold (see figure 2), which includes (a) a heterocyclic ring baring
three nitrogen atoms and two oxygen atoms, and (b) a guanidine
group, which is attached to the main ring by a linker (position Q in
figure 2).
Where possible, the dataset was divided into pairs of active and
inactive molecules that differ in only one functional group. This
resulted in 13 representative pairs of molecules that were used to
determine which specific chemical features in these molecules are
important for antagonistic activity, in addition to the main triazine
ring and guanidine group. As shown in figure 2, the four variable
positions in the scaffold - A1, D, L2, and Q, were compared
among the 13 pairs, and the activity-facilitating chemical groups at
each position were determined. These include the following
features:
(1) Positions A1 and D require an aromatic ring with a hydrogen
bond acceptor in position 4 of the ring.
(2) Position L2 may only accept the structure -NH(CH2)-.
(3) Position Q may include up to four hydrogen bond donors, a
positive ionizable feature, and an aromatic ring bearing a
hydrogen bond acceptor.
In conclusion, the SAR analysis revealed 2D chemical features
in the molecules, which may be important for receptor binding
and activation. Next, these features will be used to generate ligand-
based pharmacophore models for virtual screening (next section)
and in docking experiments to determine the plausible ligand-
receptor contacts (see below).
Ligand-based virtual screening for novel PKR binders
To identify novel potential hPKR binders, we utilized a ligand-
based procedure in which molecules are evaluated by their
similarity to a characteristic 3D fingerprint of known ligands, the
pharmacophore model. This model is a 3D ensemble of the
essential chemical features necessary to exert optimal interactions
with a specific biological target and to trigger its biological
response. The purpose of the pharmacophore modeling procedure
is to extract these chemical features from a set of known ligands
with the highest biological activity. The two most potent
(IC50,0.02 mM for intracellular Ca
2+ mobilization) hPKR
antagonists were selected from the dataset described in the
previous section, to form the training set (compounds 1 and 2,
figure S3). In addition, we also incorporated data from a third
compound published recently (compound 3 in figure S3), to ensure
good coverage of the available chemical space [38].
The HipHop algorithm [37] was used to generate common
features of pharmacophore models. This algorithm generated 10
different models, which were first tested for their ability to identify
all known active hPKR triazine-based antagonists (data not
shown). During the pharmacophore generation and analysis
procedure, we also projected the knowledge generated during
our 2D SAR analysis onto the 3D pharmacophore models, and
chose those that best fit the activity-facilitating chemical features
identified in the 2D SAR analysis previously described. The two
best models, which recaptured the highest number of known active
hPKR binders and included all required 2D features deduced
from the SAR analysis, were chosen for further analysis. The 3D
spatial relationship and geometric parameters of the models are
presented in figure 3A. Both models share a positive ionizable
feature and a hydrogen bond acceptor, corresponding to the N3
atom and O1 atoms on the main ring, respectively (figure 2).
However, the models vary in the degree of hydrophobicity
tolerated: model 2 is more restrictive, presenting one aromatic ring
feature and one hydrophobic feature, whereas model 1 is more
promiscuous, presenting two general hydrophobic features. The
aromatic/hydrophobic features correspond to positions A1 and D
of the scaffold (figure 2). Figure 3A also shows the mapping of one
of the training set molecules onto the pharmacophore model. All
four features of both models are mapped well, giving a fitness value
(FitValue) of 3.602 and 3.378 for hypotheses 1 and 2, respectively.
The fitness value measures how well the ligand fits the
pharmacophore. For a four-feature pharmacophore the maximal
FitValue is 4.
Next, we performed an enrichment study to ultimately evaluate
the pharmacophore model’s performance. Our aim was to verify
that the pharmacophores are not only able to identify the known
antagonists, but do so specifically with minimal false positives. To
this end, a dataset of 56 known active hPKR small-molecule
antagonists was seeded in a library of 5909 random molecules
retrieved from the ZINC database [39]. The random molecules
had chemical properties (such as molecular weight and formal
charge), similar to the known PKR antagonists, to ensure that the
Small-Molecule Binders of Prokineticin Receptors
PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e27990Figure 2. SAR analysis of small-molecule PKR antagonists identifies activity-determining chemical groups. The four variable positions
in the scaffold – A1, D, L2, and Q, were compared in a dataset composed of 56 active compounds (IC50,0.05 mM) and 51 inactive compounds
(IC50.1 mM) to determine the required chemical features at each position that elicit activity (a representative set is shown). These features are
indicated in dashed boxes for each position. HB - hydrogen bond.
doi:10.1371/journal.pone.0027990.g002
Figure 3. Ligand-based pharmacophore models recapture the known binders. (A) ligand-based four-feature pharmacophores used for
virtual screening, with mapping of a known active small-molecule antagonist used for constructing the pharmacophores. The pharmacophores are
represented as tolerance spheres with directional vectors where applicable. Green spheres represent hydrogen bond acceptors, red - positive
ionizable, light blue – hydrophobic, and orange - aromatic ring. (B) ROC curve demonstrating the enrichment achieved following ligand-based
pharmacophore mapping of 56 known active PKR antagonists and 5909 random molecules obtained from the ZINC database. Known actives are
significantly enriched by both pharmacophore hypotheses.
doi:10.1371/journal.pone.0027990.g003
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features.
Both models successfully identified all known compounds
embedded in the library. The quality of mapping was assessed
by generating receiver operating characteristic (ROC) curves for
each model (figure 3B), taking into consideration the ranking of
fitness values of each virtual hit. The plots provide an objective,
quantitative measure of whether a test discriminates between two
populations. As can be seen from figure 3B, both models perform
extremely well, generating almost a perfect curve. The difference
in the curves highlights the difference in pharmacophore
stringency. The stricter pharmacophore model 2 (which has an
aromatic ring feature instead of a hydrophobic feature) performs
best in identifying a large number of true positives while
maintaining a low false positive rate. Thus, we used model 2 in
the subsequent virtual screening experiments. Note that it is
possible that some of the random molecules that were identified by
the pharmacophore models, and received fitness values similar to
known antagonists, may be potential hPKR binders. A list of these
ZINC molecules is available in table S1. These compounds differ
structurally from the known small-molecule hPKR antagonists
because the maximal similarity score calculated using the
Tanimoto coefficient, between them and the known antagonists,
is 0.2626 (compounds that have Tanimoto coefficient values
.0.85 are generally considered similar to each other).
This analysis revealed that the ligand-based pharmacophore
models can be used successfully in a VLS study and that they can
identify completely different and novel scaffolds, which neverthe-
less possess the required chemical features.
hPKR1 as a potential off-target of known drugs
Recent work by Keiser and colleagues [48] utilized a chemical
similarity approach to predict new targets for established drugs.
Interestingly, they showed that although drugs are intended to be
selective, some of them do bind to several different targets, which
can explain drug side effects and efficacy, and may suggest new
indications for many drugs. Inspired by this work, we decided to
explore the possibility that hPKRs can bind established drugs.
Thus, we applied the virtual screening procedure to a dataset of
molecules retrieved from the DrugBank database (release 2.0) [40].
The DrugBank database [40] combines detailed drug (chemical,
pharmacological, and pharmaceutical) data with comprehensive
drug target (sequence, structure, and pathway) information. It
contains 4886 molecules, which include FDA-approved small-
molecule drugs, experimental drugs, FDA-approved large-mole-
cule (biotech) drugs and nutraceuticals. As a first step in the VLS
procedure, the initial dataset was pre-filtered, prior to screening,
according to the average molecular properties of known active
compounds 6 4SD. The pre-filtered set consisted of 432 molecules
that met these criteria. This set was then queried with the
pharmacophore, using the ’ligand pharmacophore mapping’
module in DS2.5 (Accelrys, Inc.). A total of 124 hits were
retrieved from the screening. Only those hits that had FitValues
above a cutoff defined according to the pharmacophores’
enrichment curve, which identifies 100% of the known antago-
nists, were further analyzed, to ensure that compatibility with the
pharmacophore of the molecules selected is as good as for the
known antagonists. This resulted in 10 hits with FitValues above
the cutoff (see figure 4). These include 3 FDA-approved drugs and
7 experimental drugs. All these compounds target enzymes,
identified by their EC numbers (corresponding to the chemical
reactions they catalyze): most of the targets are peptidases (EC
3.4.11, 3.4.21 and 3.4.23), including aminopeptidases, serine
proteases, and aspartic endopeptidases, and an additional single
compound targets a receptor protein-tyrosine kinase (EC 2.7.10).
The fact that only two classes of enzymes were identified is quite
striking, in particular, when taking into account that these two
groups combined represent only 2.6% of the targets in the
screened set. This may indicate the intrinsic ability of hPKRs to
bind compounds originally intended for this set of targets. The
calculated similarity between the known hPKR antagonists and
the hits identified using the Tanimoto coefficients is shown in
figure 4: the highest similarity score was 0.165563, indicating that
the identified hits are dissimilar from the known hPKR
antagonists, as was also observed for the ZINC hits (see Table
S1). Interestingly, when calculating the structural similarity within
the EC3.4 and 2.7.10 hits, the highest value is 0.679, indicating
consistency in the ability to recognize structurally diverse
compounds (see figure S4).
To predict which residues in the receptor may interact with the
key pharmacophores identified in the SAR analysis previously
mentioned, and to assess whether the novel ligands harboring the
essential pharmacophors fit into the binding site in the receptor,
we carried out homology modeling and docking studies of the
known and predicted ligands.
Molecular Modeling of hPKR1 predicts the small-
molecule binding site in the typical TM-bundle site of
Family A GPCRs
As a first step in analyzing small-molecule binding to hPKRs,
we generated homology models of the two subtypes, hPKR1 and
hPKR2. The models were built using the I-Tasser server [29].
These multiple-template models are based on X-ray structures of
bovine Rhodopsin (PDB codes: 1L9H) [49], the human b2-
adrenergic receptor (2RH1) [50], and the human A2A-adenosine
receptor (3EML) [51]. The overall sequence identity shared
between the PKR subtypes and each of the three templates is
approximately 20%. Although this value is quite low, it is similar
to cases in which modeling has been applied, and it satisfactorily
recaptured the binding site and binding modes [52]. Furthermore,
the sequence alignment of hPKRs and the three template
receptors are in good agreement with known structural features
of GPCRs (figure S1). Namely, all TM residues known to be highly
conserved in family A GPCRs [33] (N
1.50,D
2.50,R
3.50,W
4.50,
P
5.50,P
6.50) are properly aligned. The only exception is the
NP
7.50xxY motif in TM7, which aligns to NT
7.50LCF in hPKR1.
The initial crude homology model of hPKR1, obtained from I-
TASSER, was further refined by energy minimization and side
chain optimization. Figure 5 shows the general topology of the
refined hPKR1 model. This model exhibits the major character-
istics of family A GPCRs, including conservation of all key
residues, and a palmitoylated cysteine in the C terminal tail, which
forms a putative fourth intracellular loop. Also, similarly to family
A GPCR X-ray structures, a conserved disulfide bridge connects
the second extracellular loop (ECL2) with the extracellular end of
TM3, formed between Cys217 and Cys137, respectively. Howev-
er, both extracellular and intracellular loops are not very likely to
be modeled correctly, due to their low sequence similarity with the
template structures, and the fact that loop configurations are
highly variable among GPCR crystal structures [42]. The
emerging consensus in the field is that these models perform
better in docking and virtual screening with no modeled loops at
all than with badly modeled loops [43,44,45]. We therefore did
not include the extracellular and intracellular loops in the
subsequent analysis.
Overall, our hPKR1 model has good conservation of key
features shared among family A GPCR members. Conservation of
this fold led us to hypothesize that hPKRs possess a 7TM-bundle
Small-Molecule Binders of Prokineticin Receptors
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well-established TM bundle binding site typical of many family A
GPCRs [25]. This is in addition to a putative extracellular surface
binding site, which most likely binds the endogenous hPKR
ligands, which are small proteins. Several synthetic small-molecule
hPKR antagonists have been recently reported [17,18,19,20,38].
We hypothesized that these small molecules will occupy a pocket
within the 7TM bundle [23,53].
To identify the potential locations of a small-molecule-TM
binding site, we first mapped all receptor cavities. We then utilized
two energy-based methods, namely, Q-SiteFinder [35] and
SiteHound [36], to locate the most energetically favorable binding
sites by scanning the protein structure for the best interaction
energy with different sets of probes. The most energetically
favorable site identified by the two methods overlaps; it is located
in the upper part of the TM bundle, among TMs 3,4,5,6, and 7.
The position of the identified pocket is shown in the insert in
Figure 5.
According to the structural superposition of the hPKR1 model
on its three template structures, the predicted site is similar in
position to the well-established TM-bundle binding site of the
solved X-ray structures [54,55]. Furthermore, specific residues
lining these pockets, which are important for both agonist and
antagonist binding by GPCRs [25], are well aligned with our
model (figure S2).
Comparing the identified TM-bundle binding site between the
two subtypes revealed that they are completely conserved, except
for one residue in ECL2 - Val207 in hPKR1, which is Phe198 in
hPKR2. Figure S5 presents a superposition of the two models,
focusing on the binding site. This apparent lack of subtype
specificity in the TM-bundle binding site is in agreement with the
lack of specificity observed in activity assays of the small-molecule
triazine-based antagonists [17], which could suppress calcium
mobilization following Bv8 (a PK2 orthologue) stimulation to the
same degree, in hPKR1 and hPKR2 transfected cells [17].
We therefore will focus mainly on hPKR1 and will return to the
issue of subtype specificity in the Discussion.
Docking of known small-molecule antagonists to hPKR1
binding site and identification of important interacting
residues
To understand the mechanistic reasons for the need of
particular pharmacophores for ligands activity, one has to look
for interactions between the ligands and the receptor.
As a preliminary step, we performed a validation study, aimed
at determining whether our modeling and docking procedures can
reproduce the bound poses of representative family A GPCR
antagonist-receptor crystallographic complexes. We first per-
formed redocking of the cognate ligands carazolol and cyano-
pindolol, back to the X-ray structures from where they were
extracted and from which the loops were deleted. The results
indicate that the docking procedure can faithfully reproduce the
crystallographic complex to a very high degree (figure S6 – A–C);
with excellent ligand RMSD values of 0.89–1.2A ˚ between the
docked pose and the X-ray structure (see table S2), in accordance
with similar previous studies [44,56,57]. The redocking process
could also reproduce the majority of heavy atomic ligand-receptor
contacts observed in the X-ray complex and more generally, the
correct interacting binding site residues and specific ligand-
receptor hydrogen bonds, despite docking to loopless structures.
Next, we built homology models of b1adr and b2adr and
performed docking of the two antagonists into these models to
examine the ability of homology modeling, combined with the
docking procedure, to accurately reproduce the crystal structures.
As can be seen from figure S6 and from the ligand RMSD values
in table S2, the results can reproduce the correct positioning of the
ligand in the binding site, and at least part of the molecule can be
correctly superimposed onto the crystallized ligand, although the
resulting RMSD values are above 2A ˚. The overall prediction of
interacting binding site residues is good, correctly predicting 47–
66% of the interactions (see Table S2).
We therefore performed molecular docking of the small-
molecule hPKR antagonist dataset to the predicted hPKR1
allosteric 7TM-bundle binding site, to explore the possible
receptor-ligand interactions.
The set of 56 active and 51 inactive small-molecule antagonists
was subjected to flexible ligand – rigid receptor docking to the
hPKR1 model using LigandFit (as implemented in DS2.5,
Accelrys, Inc.) [34]. For each compound the 50 best energy
conformations were generated and docked into the binding site,
resulting in an average of 250 docked poses for each molecule.
The final ligand poses for each molecule were selected based on
the highest LigScore1 docking score, since no experimental data
regarding possible ligand contacting residues was available. The
best scoring docking poses were analyzed visually for features that
were not taken into account in the docking calculation, such as
appropriate filling of the binding site – such that the compound
fills the binding site cavity, and does not "stick out". Specific
ligand-receptor interactions were monitored across all compounds.
Figure 6 shows representative docked poses of two active (A,B) and
two inactive compounds (C,D). As shown, the active molecules
adopt a confirmation that mainly forms interactions with TMs 2,
3, and 6, such that the ligand is positioned in the center of the
cavity, blocking the entry to it and adequately filling the binding
site, as described. In contrast, the inactive small molecules are
apparently incapable of simultaneously maintaining all of these
contacts, and are positioned in different conformations that mostly
maintain interactions with only some of the TMs mentioned.
Figure 5. Homology model of hPKR1. The model is viewed
perpendicular to the plasma membrane, with the extracellular side of
the receptor shown on top, and the intracellular side shown on the
bottom of the figure. The structure is colored from the N (blue) to the C
(orange) terminal amino acid sequence. The insert shows the 7TM-
bundle allosteric small-molecule binding site, predicted by the QSite
Finder server. The binding site is located among TMs 3,4,5,6, and 7.
doi:10.1371/journal.pone.0027990.g005
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observed between the ligand and residues Arg144
3.32 and
Arg307
6.58, either through a hydrogen bond or a p-cation
interaction. The active ligands interact with at least one of these
two residues. In addition, an electrostatic interaction was observed
between the active ligands and Glu119
2.61 (as seen from figure 6A,
B). To quantify this observation, the specific interactions formed
(HB, charged, p-p and p-cation) were monitored across all the best
scoring poses of the docked ligands (active and inactive), and the
results, which represent the number of specific contacts formed
between each ligand and all polar/hydrophobic binding site
residues, were clustered (figure 7).
As shown, the hierarchical structure obtained from the
clustering procedure of receptor-ligand contacts only, clearly
separates the compounds into sub-trees that correspond to the
experimental active/inactive distinction. In the active sub-tree, the
ligands form a charged interaction with Glu119
2.61, and interact
mainly with Cys137
3.25, Arg144
3.32, and Arg307
6.58. In contrast,
in the inactive sub-tree, the molecules still form interactions with
Arg144
3.32 to some extent, but the interactions with Glu119
2.61,
Cys137
3.25, and Arg307
6.58 are drastically reduced, and instead
some of the ligands interact with Thr145
3.33 and Met332
7.47.I n
addition, some of the active ligands form either specific
interactions or van der Waals contacts with Asn141
3.29,
Phe300
6.51, and Phe324
7.39.
All of these positions have been shown experimentally to be
important for ligand binding in different family A GPCRs
members, ranging from aminergic (such as the b2-adrenergic
receptor) to peptide receptors (such as chemokine receptors) [25].
In general, the functional groups in the scaffold, which were
identified in our SAR analysis as being important for antagonist
activity, form specific interactions within the binding site (figure 8).
Namely, the main triazine ring of the scaffold forms hydrogen
bonds through its O and N atoms and p-cation interactions. The
two aromatic rings form p-cation interactions and hydrogen bonds
through the O/F/Cl atoms at position 4 of the ring, and the
positive charge at position Q and hydrogen bond donors interact
with residues from helices 2, 3, and 6, predominantly, Glu119
2.61
and Arg144
3.32, and Arg307
6.58, as described above. The
compatibility of the SAR data with the docking results supports
the predicted binding site and modes, and provides a molecular
explanation of the importance of particular pharmacophores in
the ligand.
The positions predicted to specifically bind essential functional
groups in the ligands (mainly Glu119
2.61, Arg144
3.32, and
Arg307
6.58) can be mutated in future studies, to confirm their
role in ligand binding inside the predicted TM-bundle cavity, as
recently applied to other GPCRs [58] and summarized in [25].
Docking of virtual hits to the hPKR1 model suggests
potential binders
Next, the 10 molecules identified through ligand-based virtual
screening of the DrugBank database were docked to the hPKR1
homology model. All docking experiments were performed using
LigandFit, as described in the previous section. However, here the
analysis was more strict: the resulting docked poses of each
molecule were post-processed using structure-based filters derived
Figure 6. Interaction of receptor residues with active and inactive antagonists in the allosteric hPKR1 binding site. Representative
docked poses of two known active compounds (A, B, IC50,0.05 mM), and two inactive compounds (C, D, IC50.1 mM) to the hPKR1 binding site. The
active compounds are denoted by yellow sticks and the inactive ones as orange sticks. Interacting receptor residues are denoted by cyan sticks and
labeled. Hydrogen bonds are denoted by dashed green lines and p-cation or p-p interactions are denoted by orange lines.
doi:10.1371/journal.pone.0027990.g006
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the known small-molecule antagonists and receptor residues (see
Materials and Methods for details) and were not only selected
based on the highest docking score. The underlying hypothesis is
that the same interactions are perused by the potential ligands as
by the known antagonists. Selected poses of all 10 molecules
successfully passed this procedure. All poses were visually
examined by checking that they adequately fill the binding site
and form the desired specific interactions. All 10 molecules
successfully passed this analysis and were considered as candidate
compounds that may serve as potential hPKR binders.
Next, we focused on a representative of the three FDA-
approved hits, which we identified as potential ligands for hPKRs,
namely, Indinavir, Argatroban, and Lapatinib. Figure 9 shows
representative examples of docking of Indivavir, Argatroban, and
Lapatinib to the hPKR1 binding site. As shown, the compounds
adequately fill the binding site and are predicted to form specific
interactions with residues found to be important for binding of the
known hPKR antagonists, namely, charged interaction with
Glu119
2.61, and hydrogen bonds and/or stacking interactions
with Arg144
3.32 and Arg307
6.58. These compounds also form
interactions with additional binding site residues, which interact
with the known binders (see figure 7).
Each of the compounds is widely used in the clinic, and provides
well-tested and safe compounds that may also exert their actions
via hPKRs. The potential cross-reactivity of one such candidate
drug, Indinavir, is further addressed in the Discussion.
Discussion
Prokineticin receptor (PKR) subtypes 1 and 2 are novel
members of family A GPCRs. Prokineticins and their receptors
play important roles under various physiological conditions, and
blocking PKRs may serve as a therapeutic tool for various
pathologies, including acute pain, circadian rhythm disturbances,
inflammation, and cancer.
In this study, we extracted essential functional groups from
small-molecule PKR antagonists that were previously reported,
using structure-activity relationship analysis, and we used them in
a virtual screening procedure. Consequently, we were able to
identify several potential PKR ligands with novel scaffolds.
Interestingly, the virtual hits included several HIV protease
inhibitors that are discussed next in terms of known side effects
and potential new indications of these drugs. Computational
docking of known ligands to the multiple-template 3D model of a
PKR’s structure enabled us to predict ligand-receptor contacts and
provided a structural explanation of the importance of the
chemical features we obtained from the analysis of known PKR
binders.
Homology modeling of the hPKR subtypes and docking
of known small-molecule antagonists
In this study we modeled the 3D structure of the hPKR
subtypes and explored the interactions formed between hPKR1
and small-molecule binders. Our computational analysis revealed
that hPKR1 is predicted to possess a TM-bundle binding site,
capable of binding small-molecule ligands, similarly to other
GPCR family A members, such as the aminergic receptors. This
occurs despite the fact that the receptors’ endogenous ligands are
relatively large proteins, which most likely bind the extracellular
surface of the receptors. The latter is demonstrated in experimen-
tal data on Kallmann syndrome mutations. Kallmann syndrome is
a human disease characterized by the association of hypogonad-
otropic hypogonadism and anosmia. Several loss-of-function
mutations in the human PKR2 gene have been found in
Kallmann patients [45]. Among them is the p.Q210R mutation
in ECL2 (corresponding to Q219 in hPKR1), which completely
abolishes native ligand binding and has no affinity for the
orthologue ligand MIT1 (Mamba intestinal toxin 1, which shares
60% sequence identity with PK2, and contains the essential N-
terminal motif AVITGA) [59]. Existence of both an orthosteric
extracellular binding site capable of binding small proteins and an
allosteric TM binding site was already shown in family A GPCRs.
For example, the melanin-concentrating hormone receptor
(MCHR), for which the endogenous ligand is a peptide, also
binds small-molecule antagonists in its TM-bundle cavity [60,61].
The predicted TM-bundle site is identical between the two
hPKR subtypes, except for one residue in ECL2 (Val207 in PKR1
corresponding to Phe198 in PKR2). Since this is a hydrophobic
residue in both receptors, its side chain will probably face the TM
cavity and not the solvent. Indeed, the residue was modeled to face
the TM cavity and was predicted by the energy-based methods to
be part of the TM-bundle binding site. If specific binders are
pursued in the future, this, albeit minor, difference between two
hydrophobic amino acids might be targeted.
Through docking experiments of the known hPKR antagonists,
we have identified important residues that interact at this site,
namely, Glu119
2.61, Arg144
3.32, and Arg307
6.58. These residues
form specific interactions with the chemical features of the ligand
that we found in our SAR analysis to be essential for the
molecules’ antagonistic activity. Specifically, Arg144
3.32 is analo-
gous to Asp113
3.32 of the b2-adrenergic receptor, which is an
experimentally established receptor interaction site for both
agonists and antagonists [62]. This position has also been shown
to be important for ligand binding in many other family A GPCRs
as well as in other branches of the GPCR super-family, such as the
Figure 7. Clustering of hydrogen bond, charged, and p
interaction patterns in the docked compounds correspond to
activity level. Receptor residues forming the interactions are specified
on the bottom of the clustergram. Residues denoted by p form p
interactions (either p-cation or p- p stacking). Yellow represents a
ligand-receptor contact. The sub-tree formed predominantly by the
active ligands is in green, and the one formed predominantly by
inactive ligands is in red. The ‘‘A’’ on the right side denotes active
compounds. The specific pattern formed by the active compounds is
boxed in orange. The black subtrees are mixed.
doi:10.1371/journal.pone.0027990.g007
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conserved within different family A GPCRs subfamilies, but it is
divergent among these subfamilies, for example, an Asp in the
aminergic receptors, compared with a Thr in hormone protein
receptors. It was therefore assumed that the position may play a
role in specific ligand binding within certain subfamilies [55].
Similarly, we suggest that although the residue type is divergent
between the different subfamilies (for example, a positive Arg in
the Prokineticin receptors compared with a negative Asp in
aminergic receptors), its importance in ligand binding in such
diverse receptors may be due to its spatial location in the TM-
bundle binding site. In addition, Arg307
6.58 is analogous to
Tyr290
6.58 of the GnRH receptor, which was found to be
important for binding the GnRH I and GnRH II peptide ligands
[63]. The equivalent residue at position 6.58 is also suggested, by
mutagenesis studies, to play an important role in ligand binding
and/or receptor activation of other peptide GPCRs, such as the
NK2 tachykinin receptor [64], the AT1A angiotensin receptor
[65], and the CXCR1 chemokine receptor [66]. Moreover, in the
recent crystallographic X-ray structure of the CXCR4 chemokine
receptor bound to a cyclic peptide antagonist, a specific interaction
between position 6.58 and the peptide was observed [67]. Hence,
position 6.58 may serve as a common position for the binding of
both peptides (such as the endogenous ligands PK1 and PK2) and
small-molecule ligands.
Finally, in our analysis position 2.61, which is occupied by a
Glutamic acid in hPKRs, was found to be essential for antagonist
binding, since an electrostatic interaction may be formed between
this negatively charged residue and the positive charge on the
ligand. This may explain the need for the positive charge on the
known small-molecule antagonists, which was indeed deduced
from the structure-activity analysis. The ligand’s positive charge
may interact with the negatively charged residue in receptor
position 2.61, which was also shown to be important in ligand
binding in the dopamine receptors [55].
In summary, the observed interactions reinforce the predicted
putative binding site and may support the concept that family A
GPCRs share a common small-molecule binding pocket inside the
TM cavity, regardless of the nature of their cognate ligand.
Docking of ligands to a single experimental or model structure
of a GPCR receptor has been shown to reproduce the binding
mode of the ligands in several cases [44,68,69], to enrich known
Figure 8. The essential activity-determining groups of the known binders form specific interactions with the receptor. (A) An
example of the ligand’s chemical properties, which are important for its activity, identified in the SAR analysis, and how they interact with receptor
residues. An active molecule is shown docked into the hPKR1 binding site. The activity-related chemical groups are indicated in red. The ligand is
denoted by yellow sticks. Interacting receptor residues are shown as green sticks and labeled. Hydrogen bonds are denoted by dashed green lines, p-
cation interactions are denoted by orange lines. (B) Schematic 2D representation of ligand-receptor interactions. The residues shown have at least
one atom within 4A ˚ of the ligand. Blue lines indicate hydrogen bonds and orange lines indicate hydrophobic interactions. Residues shaded in green
are involved in van der Waals interactions. Residues involved in hydrogen bonds, charge, or polar interactions are shaded in cyan.
doi:10.1371/journal.pone.0027990.g008
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and to rationalize specificity profiles of GPCR antagonists [71]
and thus was the approach taken here.
In several non-GPCR cases, good docking results have been
reported using multiple receptor conformations [72]. Such an
approach was successful for a sequence identity range of 30–60%
between models and available templates [73].
Though GPCR homology models typically have a lower
sequence identity to their potential templates, using ensembles of
multiple homology models or of a perturbed X-ray structure may
nevertheless be a viable approach, as was recently reported
[74,75,76]. Current breakthroughs in X-ray structure determina-
tion of GPCRs will enable systematic testing of the most
appropriate receptor structure representation and of docking
performance, against the benchmark of experimental structures.
Identification of potential novel hPKR binders
Our study used SAR of known hPKR binders to identify novel
potential binders of hPKR1, and highlighted possible ’off-target’
effects of FDA-approved drugs. Interestingly, the novel candidates
share little structural chemical similarity with the known hPKR
binders but share the same pharmacophores and similar putative
interactions within the TM-bundle binding site. Such a "scaffold
hopping" result is common and is often sought after in drug
discovery. The term is based on the assumption that the same
desired biological activity may be achieved by different molecules
that maintain some of the essential chemical features as the
template molecule, i.e., the molecule possesses the desired
biological activity on the target, but is structurally dissimilar
otherwise. Scaffold hopping is required, for instance, when the
central scaffold is involved in specific interactions with the target,
and changing it may lead to improved binding affinity. One
example of successful scaffold hopping, resulting in a structurally
diverse structure, is the selective D2 and D3 dopamine receptor
agonist Quinpirole [77].
The newly identified potential cross-reactivity may have two
implications – it might explain the side effects of these drugs (as
discussed next), and it might also suggest novel roles for these
drugs as potential hPKR inhibitors. One such example of potential
cross-reactivity identified through our VLS procedure is Indinavir.
Indinavir sulfate is a hydroxyaminopentane amide and a potent
and specific FDA-approved inhibitor of the HIV protease.
Indinavir acts as a competitive inhibitor, binding to the active
site of the enzyme, since it contains a hydroxyethylene scaffold that
mimics the normal peptide linkage (cleaved by the HIV protease)
but which itself cannot be cleaved. Thus, the HIV protease cannot
perform its normal function - proteolytic processing of precursor
viral proteins into mature viral proteins. Specific adverse effects
associated with Indinavir include hyperbilirubinaemia and cuta-
neous toxicities [78,79], accelerated atherosclerosis, and an
increased rate of cardiovascular disease [80]. Protease inhibitors
may cause cardiovascular disease by inducing insulin resistance,
dyslipidemia, or by endothelial dysfunction.
A study of the effects of HIV protease inhibitors on endothelial
function showed that in healthy HIV-negative subjects, Indinavir
induced impaired endothelium-dependent vasodilation after 4
weeks of treatment owing to reduced nitric oxide (NO)
production/release by the endothelial cells or reduced NO
bioavailability [81]. HIV patients treated with Indinavir presented
lower urinary excretion of the NO metabolite NO3 [82]. Wang
et al. demonstrated that Indinavir, at a clinical plasma concen-
tration, can cause endothelial dysfunction through eNOS
(endothelial nitric oxide synthase) down-regulation in porcine
pulmonary artery rings and HPAECs (human pulmonary arterial
endothelial cells), and that endothelium-dependent relaxation of
the vessel rings was also reduced following Indinavir treatment
[83].
Endothelium-derived NO is the principal vasoactive factor that
is produced by eNOS. Lin et al. showed that PK1 induced eNOS
Figure 9. Docking of potential PKR binders identified through
VLS, to the hPKR1 binding site. The proposed docked conforma-
tions of (A) Indinavir, (B) Argatroban, and (C) Lapatinib are shown. The
ligands are denoted by yellow sticks. Interacting receptor residues are
denoted by gray sticks and labeled. Hydrogen bonds are denoted by
dashed green lines, and p-cation interactions are denoted by orange
lines.
doi:10.1371/journal.pone.0027990.g009
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[14]. It has also been shown that PK1 suppressed giant contraction
in the circular muscles of mouse colon, and that this effect was
blocked by the eNOS inhibitor L-NAME. In vitro, PK1 stimulated
the release of NO from longitudinal musclemyenteric plexus
cultures [84]. We have found that PK1 treatment elevated eNOS
mRNA levels in luteal endothelial cells. Cells were also treated in
the presence of PI3/Akt pathway inhibitor, which caused a 20–
40% reduction in eNOS levels (Levit and Meidan, unpublished
data).
These opposing effects of Indinavir and PK1 on eNOS levels
and NO production/release are compatible with the chemically
based hypothesis arising from the current work, which suggests
that Indinavir can bind to the hPKR subtypes by acting as a PKR
antagonist. We suggest that this would subsequently reduce eNOS
expression levels in endothelial cells and impair NO bioavailabil-
ity, leading, at least partially, to the observed Indinavir side effects
in HIV patients. This hypothesis should be explored experimen-
tally in future studies to determine the possible binding of
Indinavir to hPKRs and its subsequent effects.
The proposed hypothesis is in accordance with the concept of
polypharmacology - specific binding and activity of a drug at two
or more molecular targets, often across target boundaries. For
example, ligands targeting aminergic family A GPCRs were also
found to act on protein kinases [85]. These "off-target" drug
actions can induce adverse side effects and increased toxicity. In
contrast, there are also cases where the drug is a "magic shotgun",
and its clinical effect results from its action on many targets, which
in turn enhances its efficacy. For example, drugs acting through
multiple GPCRs have been found to be more effective in treating
psychiatric diseases such as schizophrenia and depression [86].
This concept was demonstrated by Keiser and colleagues [48] who
utilized a statistics-based chemoinformatics approach to predict
off-targets for ,900 FDA-approved small-molecule drugs and
,2800 pharmaceutical compounds. The targets were compared
by the similarity of the ligands that bind to them. This comparison
resulted in 3832 predictions, of which 184 were inspected by
literature searches. Finally, the authors tested 30 of the predictions
experimentally, by radioligand competition binding assays. For
example, the a1 adrenergic receptor antagonist Doralese was
predicted and observed to bind to the dopamine D4 receptor (both
are aminergic GPCRs), and most interestingly, the HIV-1 reverse
transcriptase inhibitor Rescriptor was found to bind to the
histamine H4 receptor. The latter observation crosses major
target boundaries. These two targets have neither an evolutionary
or functional role nor structural similarity in common. However,
some of the known side effects of Rescriptor treatment include
painful rashes. This observation is similar to our findings of
possible interactions of Indinavir and the other enzyme-targeting
VLS hits with the PKR subtypes.
In summary, defining the selective and non-selective actions of
GPCR targeting drugs will help in advancing our understanding of
the drugs’ biological action and the observed clinical effect,
including side effects.
Potential differences between the hPKR subtypes
Both subtypes are capable of binding the cognate ligands at
approximately the same affinity [12]. Therefore, the diversification
of cellular events following activation of the subtypes [16] is not
likely to stem from the extracellular loop regions. This suggestion
warrants further experimental investigation. Our study also
suggests, in agreement with previous findings, that small-molecule
antagonists are not likely to easily differentiate between the
subtypes. This is because the TM-bundle small-molecule binding
site identified in this study is identical in its amino acid
composition for the two hPKR subtypes. Thus, an intriguing
question arises: what molecular mechanisms are responsible for
PKRs’ differential signaling patterns?
The variation of protein amino acid composition in the
extracellular and intracellular regions of PKRs is significant
(represented as black-filled circles in Fig. 1). Moreover, analysis of
the level of selection acting on the two PKR subtypes, by
calculating the ratio between non-synonymous (Ka) and synony-
mous (Ks) substitutions [46,47] predicted purifying selection for
the transmembrane helices of both subtypes (figure S7). This
analysis should be expanded in future studies, as PKR subtype
sequences from additional species become available.
The variation in amino acid composition in the intracellular
regions of the PKR subtypes may affect at least two signaling
events: receptor phosphorylation by kinases and the receptors’
coupling to G proteins. We therefore suggest that this region is
most likely to be involved in differential signaling, as detailed next.
Interaction with G proteins
Differential coupling of PKR subtypes to G proteins has been
demonstrated experimentally (reviewed in [16]). Coupling of
PKR1 to Ga11 in endothelial cells induces MAPK and PI3/Akt
phosphorylation, which promotes endothelial cell proliferation,
migration and angiogenesis [11]. In cardiomyocytes, coupling of
PKR1 to Gaq/11 induces PI3/Akt phosphorylation and protects
cardiomyocytes against hypoxic insult. In contrast, PKR2 couples
to Ga12 in endothelial cells, causing Ga12 internalization and
down-regulation of ZO-1 expression, leading to vacuolarization
and fenestration of these cells. In cardiomyocytes, PKR2 acts
through Ga12 and Gaq/11 coupling and increases cell size and
sarcomere numbers, leading to eccentric hypertrophy [16]. Thus,
sites of interactions with G-proteins may represent an additional
factor affecting PKR subtype specificity.
Receptor Phosphorylation
It is well established that GPCR phosphorylation is a complex
process involving a range of different protein kinases that can
phosphorylate the same receptor at different sites. This may result
in differential signaling outcomes, which can be tailored in a tissue-
specific manner to regulate biological processes [87]. We suggest
that part of the differential signaling of PKR subtypes may be due
to differential phosphorylation of the intracellular parts of the
receptors. Namely, phospho-acceptor sites may be missing in one
subtype or another, and analogous positions may be phosphory-
lated by different kinases due to variation in the positions
surrounding the phospho-acceptor residue (which is conserved
between subtypes), thus, changing the kinase recognition sequence
[88]. Hence, using different combinations of kinases for each
subtype results in different phosphorylation signatures. This
phosphorylation signature translates to a code that directs the
signaling outcome of the receptor. This may include two types of
signaling events: (a) common phosphorylation events for both
subtypes will mediate common regulatory features such as arrestin
recruitment and internalization and (b) subtype-specific events will
mediate specific signaling functions related to the specialized
physiological role of the receptor subtype. Preliminary analysis
using prediction tools for phosphorylation sites suggests that
Thr178 (Thr169) in the second intracellular loop and Tyr365
(Gln356) in the cytoplasmic tail of hPKR1 (hPKR2) may represent
subtype-specific phosphorylation-related sites (Levit, Meidan and
Niv, unpublished data). Further experimental studies are required
to elucidate the role of receptor phosphorylation in specific
signaling events following activation of PKR subtypes.
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In conclusion, we have identified a small-molecule TM-bundle
site that can accommodate the known small-molecule hPKR
antagonists. Hence, it can be explored in the future for designing
additional PKR-targeting compounds. The VLS procedure
identified tens of compounds that are likely to affect hPKRs.
Interestingly, FDA-approved drugs may also bind to these
receptors, and in some instances, such as with Indinavir, this
binding may provide a potential explanation for the drug’s side
effects. One residue in ECL2 is different between the two subtypes
(Val207 in hPKR1 corresponding to Phe198 in PKR2), and
several residues in the intracellular loops may affect phosphory-
lation. These residues may be exploited for designing subtype-
specific pharmacological tools, to target different pathological
conditions involving hPKRs.
Supporting Information
Figure S1 Structure-based multiple sequence alignment
of modeled PKR subtypes and X-ray structures used as
templates in the modeling procedure. Alignment was
generated by the TCoffee server. The most conserved residue in
each helix is shaded yellow and is indicated by its Ballesteros-
Weinstein numbering [33]. Identical residues are in red and
similar residues are in blue. bRho - bovine Rhodopsin (PDB
code:1L9H), hB2ADR - human b2-adrenergic receptor (2RH1),
hA2AR - human A2A adenosine receptor (3EML). The sequence
of T4 lysozyme that was fused to the hB2ADR and hA2AR
proteins to facilitate structure determination was removed prior to
alignment, for clarity.
(TIF)
Figure S2 Structural superposition of the PKR1 model
and GPCR X-ray templates used for homology model-
ing. All structures are shown in ribbon representation. PKR1 is in
turquoise, human b2-adrenergic is in orange (A), bovine rhodopsin
is in gold (B) and human A2A-adenosine receptor is in gray (C). (D)
Superposition of the hPKR1 model and the b2-adrenergic
receptor structure with emphasis on the TM-bundle binding site.
The structures are shown in a view looking down on the plane of
the membrane from the extracellular surface. Binding site residues
experimentally known to be important for ligand binding are
denoted as sticks and are labeled with Ballesteros-Weinstein
numbering. The T4 lysozyme fusion protein was removed from
the b2-adrenergic and the A2A-adenosine receptor structures, for
clarity. Structural superposition was performed using the Match-
maker module in UCFS Chimera version 1.4.1.
(TIF)
Figure S3 Structures of the three known PKR antago-
nists that were used as reference compounds for
constructing ligand-based pharmacophore models.
(TIF)
Figure S4 Structural similarity between the identified
VLS hits plotted as a heatmap. The degree of similarity was
calculated using the Tanimoto coefficient, as described in
Methods, and ranges between 0 (completely dissimilar com-
pounds) and 1 (identical compounds). Compounds with similarity
values .0.85 are usually considered structurally similar. Color
intensity corresponds to the similarity value according to the
legend. The heatmap was prepared using Matlab version
7.10.0.499 (R2010a).
(TIF)
Figure S5 Structural superposition of human PKR1 and
PKR2 models. Both structures are shown in ribbon represen-
tation, with hPKR1 in turquoise and hPKR2 in khaki. The insert shows
a detailed view of the predicted transmembrane binding site, with side
chains denoted as sticks. Structural superposition was performed using
t h eM a t c h m a k e rm o d u l ei nU C F S Chimera version 1.4.1.
(TIF)
Figure S6 Predicted binding modes of cognate ligands
redocked into crystal structures and homology models.
(A) Cyanopindolol redocked to b1adr crystal structure (PDB code:
2VT4), (B) Carazolol redocked to b1adr crystal structure (2YCW),
(C) Carazolol redocked to b2adr crystal structure (2RH1), (D)
Cyanopindolol docked to b1adr homology model, (E) Carazolol
docked to b1adr homology model and (F) Carazolol docked to
b2adr homology model. The docked ligands are shown as green
sticks. X-ray structures are represented as gray ribbons and the
crystallized ligand is shown as gray sticks. In panels (D–F) the
homology models are shown as gold ribbons.
(TIF)
Figure S7 Measure of Ka/Ks ratio on the amino acid
sequence of the PKR subtypes suggests positive selection
acting only on PKR2. Ka/Ks ratio (v) representing the ratio of
non-synonymous (Ka) to synonymous (Ks) nucleotide substitution
rates was calculated for each site for the PKR subtypes. The ratio is
plotted against the amino acid position for hPKR1 (A) and hPKR2
(B). Residues showing v.1 are indicative of positive Darwinian
selection, while residues showing v,1 are indicative of purifying
selection; the ratio for neutral selection is one (indicated on the
graph by a red line). Significant positive selection (p=0.001) was
detected only for PKR2, by the likelihood ratio test, and is
concentrated in the N-terminus and C-terminus domains.
(TIF)
Table S1 Potential hits identified from the ZINC
database.
(DOC)
Table S2 Ligand RMSD values and contact analysis for
cognate ligand docking to b1adr and b2adr crystal
structures and homology models.
(DOC)
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